甲亢性肝损害116例临床分析

目的探讨甲状腺功能亢进症（甲亢）肝损害的临床特点。方法收集228例甲亢患者的临床资料,分为肝损害组及无肝损害组,对两组患者的年龄、性别、甲亢病程、肝功能及甲状腺功能等指标进行分析比较。结果 228例甲亢患者中发生肝损害116例,发生率为50.72%。甲亢患者的性别与甲亢性肝损害的发生率无相关性;而年龄越大甲亢性肝损害发生率越高,病程越长甲亢性肝损害发生率也越高。甲亢性肝损害患者甲状腺功能指标TT4、FT3明显高于甲亢肝功能正常的患者,差异有统计学意义（P〈0.05）;肝功能测定以ALT、ALP升高多见。结论甲亢性肝损害的发病率较高,病情的严重程度与年龄、病程、甲状腺激素水平有密切关系;建议临床医生对初诊及复诊甲亢患者进行肝功能常规测定,以便合理选用治疗方案,使甲亢性肝损害得以及早治疗。     

N—acetylserotonin对肝缺血再灌注小鼠氧化应激损伤的保护作用

目的探讨NAS对肝缺血再灌注所诱导的脂质过氧化损伤产生的保护作用。方法采用夹闭肝蒂法30min、再灌注6h制作肝缺血再灌注模型,冰冻切片,HE染色,光学显微镜下观察肝细胞形态结构的变化;比色法检测损伤后血清中谷丙转氨酶（ALT）水平及肝组织中超氧化物歧化酶（SOD）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH—Px）的含量。结果夹闭肝蒂30min、再灌注6h后,肝小叶结构紊乱、肝血窦淤血,其间有白细胞浸润、肝细胞出现变性、坏死;血清中ALT水平升高,肝组织中s0D和GSH—Px的含量降低,MDA升高;NAS可减少缺血再灌注后血清ALT的释放,使肝组织中SOD和GSHPx的含量升高,MDA的含量降低;NAS＋Luz可逆转NAS的这一作用。结论NAS对肝缺血再灌注小鼠的氧化应激损伤具有保护作用。     

Direct force measurement of single DNA–peptide interactions using atomic force microscopy

The selective interactions between DNA and miniature (39 residues) engineered peptide were directly measured at the single‐molecule level by using atomic force microscopy. This peptide (p007) contains an α‐helical recognition site similar to leucine zipper GCN4 and specifically recognizes the ATGAC sequence in the DNA with nanomolar affinity. The average rupture force was 42.1 pN, which is similar to the unbinding forces of the digoxigenin–antidigoxigenin complex, one of the strongest interactions in biological systems. The single linear fit of the rupture forces versus the logarithm of pulling rates showed a single energy barrier with a transition state located at 0.74 nm from the bound state. The smaller k_off compared with that of other similar systems was presumably due to the increased stability of the helical structure by putative folding residues in p007. This strong sequence‐specific DNA–peptide interaction has a potential to be utilized to prepare well‐defined mechanically stable DNA–protein hybrid nanostructures. Copyright © 2013 John Wiley & Sons, Ltd.     

从猕猴肝脏组织扩增黄嘌呤脱氢酶／氧化酶基因片段

RT-PCR扩增猕猴黄嘌呤脱氢酶／氧化酶（XDH／XO）基因片段,为进一步开展相关研究提供实验资料。方法提取猕猴新鲜肝脏组织总RNA,用RT-PCR二步法进行XDH／XO基因片段扩增,对获得的目的片段进行序列测定,与GenBank上发表的人类（Homosapiens）、小鼠（Musmusculus）、家鼠（Rattusnorvegicus）、野猪（Susscrofa）等物种XDH／XO基因进行该序列同源性比对分析,DNAMAN软件预测该段核苷酸的氨基酸序列,Inter-ProScan及SWISS-MODEL工具进行XDH／XO的编码蛋白结构域及功能预测及三维结构构建。结果RT-PCR产物电泳检测得到了与设计大小相一致的目的条带,序列测定共测到683个核苷酸,DNAMAN软件预测该段核苷酸的氨基酸序列包括了1个编码53个氨基酸的开放阅读框（ORF）,通过该软件包中Multiplealignment对目的基因片段的核苷酸序列与NCBI报道的人类、小鼠、家鼠、野猪XDH／XO基因mRNA互补的cDNA核苷酸序列同源性进行同源性比较分析,结果显示所扩增得到的目的片段与人类同源性最高,为95．6％,与小鼠、家鼠、野猪的同源性分别为85．2％、84．3％、86．1％,说明获得的基因片段是猕猴的XDH／XO基因片段,且该基因在物种间具有较高的相似性。生物信息学预测该段XDH／XO编码蛋白含有醛氧化／脱氢酶的钼喋呤结合点结构域及黄嘌呤脱氢酶结构域。结论在体外成功扩增出猕猴XDH／XO基因片段,为进一步开展高尿酸血症致病机理研究,抗高尿酸血症新药研发奠定工作基础。     

Notch-Hif-1-alpha信号通路参与调控大鼠肝再生过程的研究

目的：探讨使用酌分泌酶抑制剂Fli-06 特异性阻断Notch 信号通路后,大鼠肝部分切除术后肝再生的情况并初步阐明 Notch-Hif-1-alpha信号通路调控肝再生的可能机制。方法：取SD 大鼠分为对照（生理盐水注射组,n=24）和抑制剂组（酌分泌酶抑制剂 注射组,n=24）。给予药物处理后,两组分别施行大鼠肝部分切除术,术后0 d,1 d,3 d,5 d,每个时间点分别留取对照组（n=6）及抑 制剂组（n=6）再生的肝组织,并检测相应肝重体重比,免疫组化法检测再生肝PCNA（增殖细胞核抗原,Proliferation Cell Nuclear Antigen）表达,RT-PCR 检测再生肝组织中的Notch1、Hes1、VEGF mRNA的变化,Western-Blot 法检测NICD（Notch 胞内段,Notch Intracellular Domain）、Hif-1-alpha（低氧诱导因子-1-alpha,Hypoxia Inducible Factor-1琢)蛋白在肝再生过程的变化情况。结果：1、肝部分切除 术后3 d和5 d,抑制剂组肝重体重比明显低于对照组差异有统计学意义（P<0.05）;2、免疫组织化学染色结果提示：抑制剂组再生 肝PCNA阳性细胞率在术后1 d,3 d,5 d 均明显低于对照组（P<0.05）;3、Western blot 结果表明：NICD 和Hif-1-alpha蛋白水平明显低 于对照组（P<0.05）;同时RT-PCR 结果提示：抑制剂组Hes1 的mRNA表达量术后1 d,3 d明显低于对照组,差异具有统计学意义 （P<0.05）。同时,抑制剂组VEGF mRNA 水平在术后3 d,5 d明显低于对照组,差异具有统计学意义（P<0.05）。结论：在大鼠肝部分 切除术后肝再生过程中,使用酌分泌酶抑制剂Fli-06 抑制Notch 信号通路后,大鼠的肝再生能力明显降低,Notch-Hif-1alpha信号通 路可能参与调控了大鼠肝部分切除术后肝再生过程。     

藏红花对肝纤维化大鼠肝脏组织中Caspase-3，Bcl-2 表达的影响

目的:研究藏红花(Saffron)对肝纤维化大鼠肝组织中半胱氨酸天冬氨酸蛋白酶-3(Caspase-3),B细胞淋巴瘤/白血病-2(Bcl-2)表达的影响。方法:45只雄性SD大鼠随机均分为3组:正常组、模型组、藏红花组,除正常组外,另外两组给予40%四氯化碳橄榄油溶液腹腔注射制备肝纤维化大鼠模型,在造模的同时,藏红花组给予藏红花溶液5 m L·kg~(-1)·d~(-1)灌胃。8周后处死大鼠,留取肝脏组织,通过Masson染色观察大鼠肝纤维化的形成,免疫组化方法检测肝组织中Caspase-3及Bcl-2蛋白表达。结果:模型组大鼠肝纤维化程度最重,藏红花组较模型组纤维化程度轻,正常组大鼠肝脏无纤维化。与模型组比,藏红花组Caspase-3在肝实质内呈弱阳性表达,而纤维间隔内表达增加;Bcl-2的表达明显减少(P0.05),正常组Caspase-3及Bcl-2几乎无表达。结论:藏红花具有抗肝纤维化作用,其机制可能与调节Caspase-3,Bcl-2的表达有关。     

A trans10-18:1 enriched fraction from beef fed a barley grain-based diet induces lipogenic gene expression and reduces viability of HepG2 cells

Beef fat is a natural source of trans (t) fatty acids, and is typically enriched with either t10-18:1 or t11-18:1. Little is known about the bioactivity of individual t-18:1 isomers, and the present study compared the effects of t9-18:1, cis (c)9-18:1 and trans (t)-18:1 fractions isolated from beef fat enriched with either t10-18:1 (HT10) or t11-18:1 (HT11). All 18:1 isomers resulted in reduced human liver (HepG2) cell viability relative to control. Both c9-18:1 and HT11were the least toxic, t9-18:1had dose response increased toxicity, and HT10 had the greatest toxicity (P<0.05). Incorporation of t18:1 isomers was 1.8–2.5 fold greater in triacylglycerol (TG) than phospholipids (PL), whereas Δ9 desaturation products were selectively incorporated into PL. Culturing HepG2 cells with t9-18:1 and HT10 increased (P<0.05) the Δ9 desaturation index (c9–16:1/16:0) compared to other fatty acid treatments. HT10 and t9-18:1 also increased expression of lipogenic genes (FAS, SCD1, HMGCR and SREBP2) compared to control (P<0.05), whereas c9-18:1 and HT11 did not affect the expression of these genes. Our results suggest effects of HT11 and c9-18:1 were similar to BSA control, whereas HT10 and t-9 18:1 (i.e. the predominant trans fatty acid isomer found in partially hydrogenated vegetable oils) were more cytotoxic and led to greater expression of lipogenic genes.     

Mapping and analyzing the human liver proteome: progress and potential

Introduction: The liver is an important organ in humans. Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world. Progress in the Human Liver Proteome Project (HLPP) has improved understanding of the liver and the liver cancer proteome.

Areas covered: Here, we summarize the recent progress in liver proteome modification profiles, proteomic studies in liver cancer, proteomic study in the search for novel liver cancer biomarkers and drug targets, and progress of the Chromosome Centric Human Proteome Project (CHPP) in the past five years in the Institutes of Biomedical Sciences (IBS) of Fudan University.

Expert commentary: Recent advances and findings discussed here provide great promise of improving the outcome of patients with liver cancer.     

参麦注射液与布地奈德联合治疗急性酒精中毒伴吸入性肺炎的临床疗效

目的:探讨参麦注射液与布地奈德联合治疗急性酒精中毒伴吸入性肺炎的临床疗效及对肝功能和炎症指标的影响。方法:选择2014年3月至2015年8月在我院接受治疗的120例急性酒精中毒伴吸入性肺炎患者为研究对象,按照随机数字表法分为治疗组和对照组,每组60例患者,对照组给予布地奈德治疗,治疗组在对照组的基础上给予参麦注射液治疗,观察两组患者的临床疗效、症状消失时间、肝功能及血清肿瘤坏死因子-α、IL-6和IL-8炎性细胞因子的变化。结果:治疗组的总有效率为95.00%显著高于对照组的83.00%,差异有统计学意义(X~2=-4.227,P=0.039)。治疗组的哮鸣音、湿罗音、咳嗽和气喘消失时间明显短于对照组,差异有统计学意义(P0.005)。治疗组的肝功能ALT、AsT和GGT明显改善,炎性因子TNF-α、IL-6和IL-8水平下降明显,差异均有统计学意义(P0.005)。结论:参麦注射液与布地奈德联合治疗急性酒精中毒伴吸入性肺炎疗效确切,可以有效缩短患者的症状消失时间,改善肝功能,减轻炎症反应,值得临床推广应用。